정규장
Log in Sign up
PDEX
PDEX
Pro-Dex Inc
7월 28일 3:28 PM ET (한국 7/29 04:28)
$57.26
+2.33 ▲ +4.24%

프로덱스(PDEX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$183M
스몰캡
P/E
15.8
적정 수준
배당수익률
없음
52주 위치
74%
저점 +144% · 고점 -17%
애널리스트
적극 매수
B-
Fundamental health
vs. Medical Instruments & Supplies
수익성 ⓘ
Top 15%
성장 ⓘ
Top 46%
밸류에이션 ⓘ
Top 50%
재무 안정 ⓘ
Top 46%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 5년 (not other companies).
Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 15원. Over the past 5년, it usually traded around 15원. Roughly in line with its own history.
Pricy doesn't mean bad — it means expectations are already baked in.
Index ⓘ RUTP/E ⓘ 15.79EPS (ttm) ⓘ 3.63Insider Own ⓘ 37.4%Shs Outstand ⓘ 3.2MPerf Week ⓘ 4.76%
Market Cap ⓘ 0.18BForward P/E ⓘ 20.6EPS next Y ⓘ -29.44%Insider Trans ⓘ -0.91%Shs Float ⓘ 2.0MPerf Month ⓘ -12.33%
Enterprise Value ⓘ 0.19BPEG ⓘ -EPS next Q ⓘ 0.67Inst Own ⓘ 32.13%Short Float ⓘ 7.85%Perf Quarter ⓘ 9.9%
Income ⓘ 0.01BP/S ⓘ 2.45EPS this Y ⓘ 47.57%Inst Trans ⓘ -0.54%Short Ratio ⓘ 2.34Perf Half Y ⓘ 46.37%
Sales ⓘ 0.07BP/B ⓘ 4.05EPS next 5Y ⓘ -ROA ⓘ 17.24%Short Interest ⓘ 0.16MPerf YTD ⓘ 48.8%
Book/sh ⓘ 14.14P/C ⓘ 16.65EPS past 3/5Y ⓘ 30.03% 12.25%ROE ⓘ 29.83%52W High ⓘ -17% ($68.99)Perf Year ⓘ 15.84%
Cash/sh ⓘ 3.44P/FCF ⓘ 26.23Sales past 3/5Y ⓘ 16.57% 13.84%ROIC ⓘ 19.89%52W Low ⓘ 143.97% ($23.47)Perf 3Y ⓘ 208.08%
Dividend Est. ⓘ -EV/EBITDA ⓘ 15.86EPS Y/Y TTM ⓘ 29.86%Gross Margin ⓘ 28.29%Volatility(W/M) ⓘ 4.96% 6.55%Perf 5Y ⓘ 94.43%
Dividend TTM ⓘ -EV/Sales ⓘ 2.57Sales Y/Y TTM ⓘ 16.39%Oper. Margin ⓘ 14.48%ATR (14) ⓘ 3.48Perf 10Y ⓘ 931.71%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 2.14EPS Q/Q ⓘ 22.74%Profit Margin ⓘ 16.08%RSI (14) ⓘ 46.74Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 3.67Sales Q/Q ⓘ 14.56%SMA20 ⓘ -2.14% ($58.51)Beta ⓘ 0.03Target Price ⓘ $70
Payout ⓘ -Debt/Eq ⓘ 0.45Earnings ⓘ 2026/4/30SMA50 ⓘ -6.98% ($61.56)Rel Volume ⓘ 1.29Prev Close ⓘ $54.93
Employees ⓘ 181LT Debt/Eq ⓘ 0.33EPS/Sales Surpr. ⓘ -SMA200 ⓘ 22.83% ($46.62)Avg Volume(3M) ⓘ 0.07MPrice ⓘ $57.26
IPO ⓘ 1986/8/7Option/Short ⓘ No/YesTrades ⓘ 1535Volume ⓘ 86,702Change ⓘ 4.24%
Quarterly earnings trend SEC filings · USD
24.6*
24.9
24.12
25.3
25.6*
25.9
25.12
26.3
Revenue Net income 최근 분기: 매출 $20M (YoY +15%) · 순이익 $4M (YoY +20%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Pro-Dex Inc (PDEX) Investment Analysis

What kind of company is Pro-Dex Inc?

프로덱스(PDEX) 방어주
Healthcare · Medical Instruments & Supplies
Small-Cap — Low Volume, High Volatility

🔩 Pro-Dex (PDEX) is a U.S. medical device contract manufacturer that designs and produces autoclavable, battery- and electric-powered surgical drivers and shavers used in orthopedic and craniomaxillofacial procedures. Leveraging its proprietary torque-limiting technology, the company supplies critical surgical handpieces to major medical device OEM customers, and is distinguished by its vertically integrated capabilities that span the entire process from design through full-scale production.

Learn more about Pro-Dex Inc →
Market Cap
$0.2B
Approx. KRW 0.3 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank4162
Employees181people
IPO1986/08/07
Current Price$57.26 ≈ 78,446원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 4월 30일 (목) · 장 마감 후
🔔 Earnings release 2026년 1월 29일 (목) · 장 마감 후

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
14.5%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies 초소형주 Median -41.1% · Top 18%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
16.1%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies 초소형주 Median -29.9% · Top 7%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
28.3%
✓ 평균
My positionMid-range
Low range Average High range
Medical Instruments & Supplies 초소형주 Median 37.8% · Bottom 37%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
29.8%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 초소형주 Median -98.0% · Top tier
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
17.2%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 초소형주 Median -59.3% · Top tier
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
19.9%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 초소형주 Median -77.3% · Top tier
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.45
✓ Healthy debt
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 0.26
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
3.67
✓ 양호
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 2.34
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.14
✓ 양호
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 1.97
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$70.00
현재가 대비 +22.2%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
20.60배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
내년 EPS 예상 성장률
-29.4%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+47.6%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median 21.2% · Top 36%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
-29.4%
부진
My positionBottom 25%
Low range Average High range
방어주 초소형주 Median 14.5% · Bottom 12%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+30.0%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median 30.0% · Around average
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+12.3%
평균
My positionMid-range
Low range Average High range
방어주 초소형주 Median 16.4% · Bottom 46%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+13.8%
우수
My positionTop 25%
Low range Average High range
방어주 초소형주 Median 2.1% · Top 16%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+14.6%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median -4.5% · Top 30%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Slightly outperformed the market over 5 years (+26%p)
PDEX +94.4% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
+26.1%p
ahead of the market
vs Health Care (XLV)
+69.9%p
well ahead of the sector average
1-year basis
vs S&P 500
-0.2%p
roughly in line with the market
vs Health Care (XLV)
-3.9%p
roughly in line with the sector average
Rank among peers
5-year return Top among peers Based on 18 peers
1-year return Top among peers Based on 23 peers
Current position within 52-week range
Low (-144.0%p) High (-17.0%p)
Current price is 144.0% above the 52-week low and 17.0% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-20.8%
Annualized volatility
48.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $57.26 below the midline ($58.51). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -1.728 < Signal -1.384 in negative zone + Hist negative (-0.344). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 46.7 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 40.6.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Cheap on Vs. Earnings, Pricey on Vs. Assets, In line with peers on Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Pricey
🧾 Vs. Sales Mid-range
💧 Vs. Cash Flow Mid-range
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
15.79x
✓ Very cheap
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies median 35.22x · Top 18% — relatively cheap within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
20.60x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 18.44x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
4.05x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies 초소형주 median 1.95x · Bottom 25% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
2.45x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies 초소형주 median 2.38x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
15.86x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 14.76x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
26.23x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 25.16x · Around the industry average
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$70.00 vs. current price +22.2%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Medical Instruments & Supplies

Who owns it?

Ownership flow shows some pressure
Insider modest net selling -0.9% · Institutional modest net selling -0.5% · Short interest moderate 7.8% · Short interest fell -3.6%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-0.9%
Insiders net selling
🏦 Institutions (funds & investors)
-0.5%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 32.1%
Moderate institutional participation
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 37.4%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 30.5%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
7.8%
Moderate
Healthcare 초소형주 Median 3.9%
Past 90 days 📉 -3.6%p decrease
Short interest days to cover
2.3 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 3.2M주
Float (tradable shares) 2.0M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding PDEX

ETFs with the highest weightings · 10 total shown
QQQS
QQQS
Invesco NASDAQ Future Gen 200 ETF
0.57%
$21M
ROSC
ROSC
Hartford Multifactor Small Cap ETF
0.32%
$61M
SQLV
SQLV
Royce Quant Small-Cap Quality Value ETF
0.16%
$29M
FDM
FDM
First Trust Dow Jones Select Microcap Index Fund
0.12%
$260M
IWC
IWC
iShares Micro-Cap ETF
0.02%
$1.4B
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
PDEX PDEX This Stock
$182.8M15.8 ▲4.0 ▼29.83% ▲- +4.2%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
프로덱스(PDEX) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
프로덱스(PDEX)는 정형외과용 멸균 전동식 수술 드라이버를 대형 OEM에 공급하는 미국 의료기기 위탁 제조 기업으로, 신형 핸드피스 기반 매출 성장과 고마진 구조, 그리고 고객 집중 리스크가 주가·실적·전망의 핵심 변수입니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 프로덱스(PDEX)?

프로덱스(PDEX) belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is the market cap of PDEX?

The market cap of PDEX is approximately $183M, ranking 4,162 within its sector.

What is the P/E ratio of PDEX?

PDEX has a P/E ratio of approximately 15.8x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for PDEX?

PDEX has recorded a 52-week high of $68.99 and a low of $23.47.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.